Midostaurin
别名: PKC412, CGP 41251 中文名称：米哚妥林
Midostaurin 是一种多靶点激酶抑制剂，作用于PKCα/β/γ， Syk， Flk-1， Akt， PKA， c-Kit， c-Fgr， c-Src， FLT3， PDFRβ和VEGFR1/2，IC50为80-500 nM。
-chemical-structure-s8064.gif)
Midostaurin Chemical Structure
CAS: 120685-11-2
产品质控
批次：
纯度：
99.98%
99.98
Midostaurin相关产品
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| EOL-1 | Apoptosis assay | 10 nM | 72 hrs | Induction of apoptosis in human EOL-1 cells assessed as caspase-3 activation at 10 nM after 72 hrs by immunoblotting analysis | 29350920 |
| MOLM13 | Apoptosis assay | 10 nM | 72 hrs | Induction of apoptosis in human MOLM13 cells assessed as caspase-3 activation at 10 nM after 72 hrs by immunoblotting analysis | 29350920 |
| U937 | Cytotoxicity assay | 72 hrs | Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 1.4 μM. | 26081023 | |
| RS4:11 | Function assay | 72 hrs | Inhibition of wild type homozygous FLT3 in human RS4:11 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.4 μM. | 26081023 | |
| Sf9 | Function assay | 120 mins | Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay, IC50 = 0.25 μM. | 26081023 | |
| FDC-P1 | Function assay | 48 hrs | Inhibition of mouse GM-CSF-stimulated cell proliferation of growth factor dependent mouse FDC-P1 cells expressing human FMS after 48 hrs by resazurin dye reduction assay, IC50 = 0.2 μM. | 20156689 | |
| A375 | Toxicity assay | 72 hrs | Toxicity against human A375 cells after 72 hrs by cell titer-blue assay, IC50 = 0.18 μM. | 19654408 | |
| FDC-P1 | Function assay | 48 hrs | Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay, IC50 = 0.142 μM. | 20156689 | |
| Sf9 | Function assay | 90 mins | Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay, IC50 = 0.08 μM. | 26081023 | |
| MOLM-13 | Function assay | 72 hrs | Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.055 μM. | 26081023 | |
| MV4-11 | Function assay | 72 hrs | Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.038 μM. | 26081023 | |
| Sf9 | Function assay | 4 hrs | Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay, IC50 = 0.037 μM. | 26081023 | |
| RS4-11 | Function assay | 2 hrs | Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay, IC50 = 0.015 μM. | 19654408 | |
| RS4-11 | Function assay | 2 hrs | Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay, IC50 = 0.013 μM. | 19654408 | |
| MV4-11 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay, IC50 = 0.012 μM. | 19654408 | |
| MOLM13 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MOLM13 cells after 72 hrs by MTS assay, IC50 = 0.0047 μM. | 29350920 | |
| EOL-1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human EOL-1 cells after 72 hrs by MTS assay, IC50 = 0.0038 μM. | 29350920 | |
| D-336MG | Growth Inhibition Assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50 = 0.08754 μM. | SANGER | ||
| HCC1395 | Growth Inhibition Assay | Inhibition of human HCC1395 cell growth in a cell viability assay, IC50 = 0.08428 μM. | SANGER | ||
| MES-SA | Growth Inhibition Assay | Inhibition of human MES-SA cell growth in a cell viability assay, IC50 = 0.07544 μM. | SANGER | ||
| NCI-H1755 | Growth Inhibition Assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50 = 0.06273 μM. | SANGER | ||
| KASUMI-1 | Growth Inhibition Assay | Inhibition of human KASUMI-1 cell growth in a cell viability assay, IC50 = 0.06016 μM. | SANGER | ||
| EoL-1-cell | Growth Inhibition Assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50 = 0.05208 μM. | SANGER | ||
| SW982 | Growth Inhibition Assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50 = 0.04558 μM. | SANGER | ||
| CGTH-W-1 | Growth Inhibition Assay | Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50 = 0.04265 μM. | SANGER | ||
| NKM-1 | Growth Inhibition Assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50 = 0.03942 μM. | SANGER | ||
| MV-4-11 | Growth Inhibition Assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 0.01983 μM. | SANGER | ||
| SN12C | Function assay | Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Adherent), Potency = 1.6626 μM. | ChEMBL | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| BAF3 | Antiproliferative assay | Antiproliferative activity against mouse BAF3 cells transformed with ZNF198-FGFR1 construct, IC50 = 0.2 μM. | 21936542 | ||
| CHP-212 | Growth Inhibition Assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50 = 0.08773 μM. | SANGER | ||
| KM12 | Growth Inhibition Assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 0.09275 μM. | SANGER | ||
| A204 | Growth Inhibition Assay | Inhibition of human A204 cell growth in a cell viability assay, IC50 = 0.10052 μM. | SANGER | ||
| CAL-51 | Growth Inhibition Assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50 = 0.10709 μM. | SANGER | ||
| NALM-6 | Growth Inhibition Assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50 = 0.10803 μM. | SANGER | ||
| NCI-H2342 | Growth Inhibition Assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50 = 0.10881 μM. | SANGER | ||
| MONO-MAC-6 | Growth Inhibition Assay | Inhibition of human MONO-MAC-6 cell growth in a cell viability assay, IC50 = 0.11136 μM. | SANGER | ||
| A431 | Growth Inhibition Assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 0.11216 μM. | SANGER | ||
| LC-2-ad | Growth Inhibition Assay | Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50 = 0.11345 μM. | SANGER | ||
| NCI-H650 | Growth Inhibition Assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50 = 0.11708 μM. | SANGER | ||
| KGN | Growth Inhibition Assay | Inhibition of human KGN cell growth in a cell viability assay, IC50 = 0.11741 μM. | SANGER | ||
| A427 | Growth Inhibition Assay | Inhibition of human A427 cell growth in a cell viability assay, IC50 = 0.11918 μM. | SANGER | ||
| 769-P | Growth Inhibition Assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 0.12082 μM. | SANGER | ||
| EFO-21 | Growth Inhibition Assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50 = 0.12972 μM. | SANGER | ||
| KS-1 | Growth Inhibition Assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 0.13006 μM. | SANGER | ||
| SNU-449 | Growth Inhibition Assay | Inhibition of human SNU-449 cell growth in a cell viability assay, IC50 = 0.1317 μM. | SANGER | ||
| SW1710 | Growth Inhibition Assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50 = 0.13316 μM. | SANGER | ||
| ABC-1 | Growth Inhibition Assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50 = 0.13415 μM. | SANGER | ||
| NY | Growth Inhibition Assay | Inhibition of human NY cell growth in a cell viability assay, IC50 = 0.13748 μM. | SANGER | ||
| SNU-387 | Growth Inhibition Assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50 = 0.13872 μM. | SANGER | ||
| H4 | Growth Inhibition Assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 0.13963 μM. | SANGER | ||
| ALL-PO | Growth Inhibition Assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50 = 0.14546 μM. | SANGER | ||
| HuO-3N1 | Growth Inhibition Assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50 = 0.15463 μM. | SANGER | ||
| LB1047-RCC | Growth Inhibition Assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50 = 0.15487 μM. | SANGER | ||
| HT-1080 | Growth Inhibition Assay | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50 = 0.15982 μM. | SANGER | ||
| PANC-03-27 | Growth Inhibition Assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 0.1602 μM. | SANGER | ||
| MG-63 | Growth Inhibition Assay | Inhibition of human MG-63 cell growth in a cell viability assay, IC50 = 0.16437 μM. | SANGER | ||
| TCCSUP | Growth Inhibition Assay | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50 = 0.16469 μM. | SANGER | ||
| KYSE-270 | Growth Inhibition Assay | Inhibition of human KYSE-270 cell growth in a cell viability assay, IC50 = 0.16778 μM. | SANGER | ||
| GDM-1 | Growth Inhibition Assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50 = 0.17262 μM. | SANGER | ||
| HUTU-80 | Growth Inhibition Assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50 = 0.17279 μM. | SANGER | ||
| AGS | Growth Inhibition Assay | Inhibition of human AGS cell growth in a cell viability assay, IC50 = 0.17352 μM. | SANGER | ||
| MFH-ino | Growth Inhibition Assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50 = 0.17455 μM. | SANGER | ||
| HuCCT1 | Growth Inhibition Assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 0.17856 μM. | SANGER | ||
| HOP-62 | Growth Inhibition Assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50 = 0.18073 μM. | SANGER | ||
| CAS-1 | Growth Inhibition Assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50 = 0.18165 μM. | SANGER | ||
| PA-1 | Growth Inhibition Assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50 = 0.18499 μM. | SANGER | ||
| T98G | Growth Inhibition Assay | Inhibition of human T98G cell growth in a cell viability assay, IC50 = 0.18995 μM. | SANGER | ||
| GI-ME-N | Growth Inhibition Assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50 = 0.19475 μM. | SANGER | ||
| YKG-1 | Growth Inhibition Assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 0.19568 μM. | SANGER | ||
| U031 | Growth Inhibition Assay | Inhibition of human U031 cell growth in a cell viability assay, IC50 = 0.19698 μM. | SANGER | ||
| 8-MG-BA | Growth Inhibition Assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50 = 0.1981 μM. | SANGER | ||
| G-402 | Growth Inhibition Assay | Inhibition of human G-402 cell growth in a cell viability assay, IC50 = 0.20253 μM. | SANGER | ||
| G-361 | Growth Inhibition Assay | Inhibition of human G-361 cell growth in a cell viability assay, IC50 = 0.20853 μM. | SANGER | ||
| CAL-54 | Growth Inhibition Assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 0.20859 μM. | SANGER | ||
| NTERA-S-cl-D1 | Growth Inhibition Assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50 = 0.20895 μM. | SANGER | ||
| NCI-H810 | Growth Inhibition Assay | Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50 = 0.21027 μM. | SANGER | ||
| CAL-120 | Growth Inhibition Assay | Inhibition of human CAL-120 cell growth in a cell viability assay, IC50 = 0.21061 μM. | SANGER | ||
| EFM-19 | Growth Inhibition Assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50 = 0.21213 μM. | SANGER | ||
| LCLC-103H | Growth Inhibition Assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50 = 0.21496 μM. | SANGER | ||
| CAKI-1 | Growth Inhibition Assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50 = 0.21505 μM. | SANGER | ||
| G-401 | Growth Inhibition Assay | Inhibition of human G-401 cell growth in a cell viability assay, IC50 = 0.22339 μM. | SANGER | ||
| NMC-G1 | Growth Inhibition Assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50 = 0.22359 μM. | SANGER | ||
| NCI-H2030 | Growth Inhibition Assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50 = 0.23006 μM. | SANGER | ||
| HCT-116 | Growth Inhibition Assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 0.23568 μM. | SANGER | ||
| SNU-423 | Growth Inhibition Assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50 = 0.23657 μM. | SANGER | ||
| SCC-4 | Growth Inhibition Assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 0.23967 μM. | SANGER | ||
| SF126 | Growth Inhibition Assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50 = 0.24731 μM. | SANGER | ||
| HSC-2 | Growth Inhibition Assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50 = 0.24734 μM. | SANGER | ||
| VA-ES-BJ | Growth Inhibition Assay | Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50 = 0.24883 μM. | SANGER | ||
| MHH-ES-1 | Growth Inhibition Assay | Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50 = 0.2494 μM. | SANGER | ||
| D-247MG | Growth Inhibition Assay | Inhibition of human D-247MG cell growth in a cell viability assay, IC50 = 0.25013 μM. | SANGER | ||
| CCF-STTG1 | Growth Inhibition Assay | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50 = 0.25335 μM. | SANGER | ||
| BFTC-905 | Growth Inhibition Assay | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50 = 0.25458 μM. | SANGER | ||
| YT | Growth Inhibition Assay | Inhibition of human YT cell growth in a cell viability assay, IC50 = 0.26282 μM. | SANGER | ||
| KYSE-150 | Growth Inhibition Assay | Inhibition of human KYSE-150 cell growth in a cell viability assay, IC50 = 0.26282 μM. | SANGER | ||
| NCI-H28 | Growth Inhibition Assay | Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50 = 0.26585 μM. | SANGER | ||
| MC-IXC | Growth Inhibition Assay | Inhibition of human MC-IXC cell growth in a cell viability assay, IC50 = 0.26629 μM. | SANGER | ||
| SW48 | Growth Inhibition Assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 0.2668 μM. | SANGER | ||
| SF295 | Growth Inhibition Assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50 = 0.27257 μM. | SANGER | ||
| 8505C | Growth Inhibition Assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50 = 0.27604 μM. | SANGER | ||
| ONS-76 | Growth Inhibition Assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50 = 0.27841 μM. | SANGER | ||
| CAL-12T | Growth Inhibition Assay | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50 = 0.28001 μM. | SANGER | ||
| MDA-MB-231 | Growth Inhibition Assay | Inhibition of human MDA-MB-231 cell growth in a cell viability assay, IC50 = 0.28101 μM. | SANGER | ||
| GCIY | Growth Inhibition Assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50 = 0.28692 μM. | SANGER | ||
| DoTc2-4510 | Growth Inhibition Assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50 = 0.29002 μM. | SANGER | ||
| A172 | Growth Inhibition Assay | Inhibition of human A172 cell growth in a cell viability assay, IC50 = 0.2915 μM. | SANGER | ||
| BCPAP | Growth Inhibition Assay | Inhibition of human BCPAP cell growth in a cell viability assay, IC50 = 0.29879 μM. | SANGER | ||
| LB831-BLC | Growth Inhibition Assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50 = 0.29946 μM. | SANGER | ||
| COLO-792 | Growth Inhibition Assay | Inhibition of human COLO-792 cell growth in a cell viability assay, IC50 = 0.29972 μM. | SANGER | ||
| BFTC-909 | Growth Inhibition Assay | Inhibition of human BFTC-909 cell growth in a cell viability assay, IC50 = 0.3107 μM. | SANGER | ||
| KYSE-410 | Growth Inhibition Assay | Inhibition of human KYSE-410 cell growth in a cell viability assay, IC50 = 0.31254 μM. | SANGER | ||
| EW-16 | Growth Inhibition Assay | Inhibition of human EW-16 cell growth in a cell viability assay, IC50 = 0.3143 μM. | SANGER | ||
| SK-MES-1 | Growth Inhibition Assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 0.31485 μM. | SANGER | ||
| DU-145 | Growth Inhibition Assay | Inhibition of human DU-145 cell growth in a cell viability assay, IC50 = 0.31889 μM. | SANGER | ||
| GI-1 | Growth Inhibition Assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50 = 0.31902 μM. | SANGER | ||
| AN3-CA | Growth Inhibition Assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 0.32198 μM. | SANGER | ||
| EW-18 | Growth Inhibition Assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50 = 0.32233 μM. | SANGER | ||
| NCI-H2122 | Growth Inhibition Assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50 = 0.32285 μM. | SANGER | ||
| BB30-HNC | Growth Inhibition Assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50 = 0.32367 μM. | SANGER | ||
| DMS-273 | Growth Inhibition Assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50 = 0.32388 μM. | SANGER | ||
| SK-UT-1 | Growth Inhibition Assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50 = 0.32952 μM. | SANGER | ||
| LXF-289 | Growth Inhibition Assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50 = 0.32965 μM. | SANGER | ||
| NCI-H1792 | Growth Inhibition Assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50 = 0.33096 μM. | SANGER | ||
| ACHN | Growth Inhibition Assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50 = 0.33117 μM. | SANGER | ||
| D-392MG | Growth Inhibition Assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50 = 0.3312 μM. | SANGER | ||
| MCF7 | Growth Inhibition Assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50 = 0.33274 μM. | SANGER | ||
| HCT-15 | Growth Inhibition Assay | Inhibition of human HCT-15 cell growth in a cell viability assay, IC50 = 0.33432 μM. | SANGER | ||
| OS-RC-2 | Growth Inhibition Assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50 = 0.33512 μM. | SANGER | ||
| NCI-H358 | Growth Inhibition Assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50 = 0.33551 μM. | SANGER | ||
| HLE | Growth Inhibition Assay | Inhibition of human HLE cell growth in a cell viability assay, IC50 = 0.33752 μM. | SANGER | ||
| SW1088 | Growth Inhibition Assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50 = 0.33797 μM. | SANGER | ||
| MRK-nu-1 | Growth Inhibition Assay | Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50 = 0.3396 μM. | SANGER | ||
| C-4-II | Growth Inhibition Assay | Inhibition of human C-4-II cell growth in a cell viability assay, IC50 = 0.34889 μM. | SANGER | ||
| ST486 | Growth Inhibition Assay | Inhibition of human ST486 cell growth in a cell viability assay, IC50 = 0.34939 μM. | SANGER | ||
| NCI-H2405 | Growth Inhibition Assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50 = 0.35115 μM. | SANGER | ||
| SK-LMS-1 | Growth Inhibition Assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50 = 0.35335 μM. | SANGER | ||
| PANC-10-05 | Growth Inhibition Assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50 = 0.35633 μM. | SANGER | ||
| K5 | Growth Inhibition Assay | Inhibition of human K5 cell growth in a cell viability assay, IC50 = 0.36149 μM. | SANGER | ||
| SR | Growth Inhibition Assay | Inhibition of human SR cell growth in a cell viability assay, IC50 = 0.36571 μM. | SANGER | ||
| Calu-3 | Growth Inhibition Assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50 = 0.36825 μM. | SANGER | ||
| VMRC-RCZ | Growth Inhibition Assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50 = 0.36935 μM. | SANGER | ||
| COR-L105 | Growth Inhibition Assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 0.37071 μM. | SANGER | ||
| ETK-1 | Growth Inhibition Assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50 = 0.37693 μM. | SANGER | ||
| GT3TKB | Growth Inhibition Assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 0.38043 μM. | SANGER | ||
| PF-382 | Growth Inhibition Assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50 = 0.38756 μM. | SANGER | ||
| HT-144 | Growth Inhibition Assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 0.38948 μM. | SANGER | ||
| TK10 | Growth Inhibition Assay | Inhibition of human TK10 cell growth in a cell viability assay, IC50 = 0.39144 μM. | SANGER | ||
| IGR-1 | Growth Inhibition Assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 0.39369 μM. | SANGER | ||
| SF268 | Growth Inhibition Assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50 = 0.39381 μM. | SANGER | ||
| L-540 | Growth Inhibition Assay | Inhibition of human L-540 cell growth in a cell viability assay, IC50 = 0.39454 μM. | SANGER | ||
| SK-MEL-30 | Growth Inhibition Assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50 = 0.39913 μM. | SANGER | ||
| KYSE-520 | Growth Inhibition Assay | Inhibition of human KYSE-520 cell growth in a cell viability assay, IC50 = 0.40238 μM. | SANGER | ||
| RXF393 | Growth Inhibition Assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50 = 0.40604 μM. | SANGER | ||
| A704 | Growth Inhibition Assay | Inhibition of human A704 cell growth in a cell viability assay, IC50 = 0.40917 μM. | SANGER | ||
| HCE-4 | Growth Inhibition Assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50 = 0.4101 μM. | SANGER | ||
| SW780 | Growth Inhibition Assay | Inhibition of human SW780 cell growth in a cell viability assay, IC50 = 0.41142 μM. | SANGER | ||
| TUR | Growth Inhibition Assay | Inhibition of human TUR cell growth in a cell viability assay, IC50 = 0.41374 μM. | SANGER | ||
| D-263MG | Growth Inhibition Assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50 = 0.41413 μM. | SANGER | ||
| NCI-H1563 | Growth Inhibition Assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50 = 0.41484 μM. | SANGER | ||
| MZ1-PC | Growth Inhibition Assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 0.41783 μM. | SANGER | ||
| MKN45 | Growth Inhibition Assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50 = 0.41931 μM. | SANGER | ||
| MDA-MB-157 | Growth Inhibition Assay | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50 = 0.42015 μM. | SANGER | ||
| RKO | Growth Inhibition Assay | Inhibition of human RKO cell growth in a cell viability assay, IC50 = 0.42017 μM. | SANGER | ||
| NCI-H522 | Growth Inhibition Assay | Inhibition of human NCI-H522 cell growth in a cell viability assay, IC50 = 0.423 μM. | SANGER | ||
| ECC12 | Growth Inhibition Assay | Inhibition of human ECC12 cell growth in a cell viability assay, IC50 = 0.42923 μM. | SANGER | ||
| COLO-205 | Growth Inhibition Assay | Inhibition of human COLO-205 cell growth in a cell viability assay, IC50 = 0.43222 μM. | SANGER | ||
| EW-13 | Growth Inhibition Assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50 = 0.43548 μM. | SANGER | ||
| CAL-39 | Growth Inhibition Assay | Inhibition of human CAL-39 cell growth in a cell viability assay, IC50 = 0.43719 μM. | SANGER | ||
| MPP-89 | Growth Inhibition Assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50 = 0.43945 μM. | SANGER | ||
| SK-LU-1 | Growth Inhibition Assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50 = 0.43985 μM. | SANGER | ||
| HuO9 | Growth Inhibition Assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50 = 0.44135 μM. | SANGER | ||
| NCI-H2170 | Growth Inhibition Assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50 = 0.44353 μM. | SANGER | ||
| HOS | Growth Inhibition Assay | Inhibition of human HOS cell growth in a cell viability assay, IC50 = 0.45888 μM. | SANGER | ||
| CCRF-CEM | Growth Inhibition Assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50 = 0.47081 μM. | SANGER | ||
| COLO-680N | Growth Inhibition Assay | Inhibition of human COLO-680N cell growth in a cell viability assay, IC50 = 0.47106 μM. | SANGER | ||
| 786-0 | Growth Inhibition Assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 0.47344 μM. | SANGER | ||
| EFE-184 | Growth Inhibition Assay | Inhibition of human EFE-184 cell growth in a cell viability assay, IC50 = 0.47346 μM. | SANGER | ||
| A2780 | Growth Inhibition Assay | Inhibition of human A2780 cell growth in a cell viability assay, IC50 = 0.47503 μM. | SANGER | ||
| A498 | Growth Inhibition Assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 0.47693 μM. | SANGER | ||
| KYSE-180 | Growth Inhibition Assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50 = 0.47825 μM. | SANGER | ||
| SIG-M5 | Growth Inhibition Assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50 = 0.48299 μM. | SANGER | ||
| NCI-H2009 | Growth Inhibition Assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50 = 0.48689 μM. | SANGER | ||
| BC-3 | Growth Inhibition Assay | Inhibition of human BC-3 cell growth in a cell viability assay, IC50 = 0.48741 μM. | SANGER | ||
| MEL-JUSO | Growth Inhibition Assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50 = 0.49214 μM. | SANGER | ||
| SH-4 | Growth Inhibition Assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 0.49271 μM. | SANGER | ||
| SNG-M | Growth Inhibition Assay | Inhibition of human SNG-M cell growth in a cell viability assay, IC50 = 0.49283 μM. | SANGER | ||
| BxPC-3 | Growth Inhibition Assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 0.49366 μM. | SANGER | ||
| HCC38 | Growth Inhibition Assay | Inhibition of human HCC38 cell growth in a cell viability assay, IC50 = 0.49828 μM. | SANGER | ||
| SK-HEP-1 | Growth Inhibition Assay | Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50 = 0.51297 μM. | SANGER | ||
| REH | Growth Inhibition Assay | Inhibition of human REH cell growth in a cell viability assay, IC50 = 0.51334 μM. | SANGER | ||
| NCI-H1299 | Growth Inhibition Assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50 = 0.51572 μM. | SANGER | ||
| SK-CO-1 | Growth Inhibition Assay | Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50 = 0.51849 μM. | SANGER | ||
| EFO-27 | Growth Inhibition Assay | Inhibition of human EFO-27 cell growth in a cell viability assay, IC50 = 0.52524 μM. | SANGER | ||
| A2058 | Growth Inhibition Assay | Inhibition of human A2058 cell growth in a cell viability assay, IC50 = 0.52844 μM. | SANGER | ||
| GCT | Growth Inhibition Assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 0.52897 μM. | SANGER | ||
| EW-1 | Growth Inhibition Assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50 = 0.53155 μM. | SANGER | ||
| PC-14 | Growth Inhibition Assay | Inhibition of human PC-14 cell growth in a cell viability assay, IC50 = 0.53855 μM. | SANGER | ||
| KG-1 | Growth Inhibition Assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 0.55419 μM. | SANGER | ||
| LU-99A | Growth Inhibition Assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50 = 0.55849 μM. | SANGER | ||
| DEL | Growth Inhibition Assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 0.55898 μM. | SANGER | ||
| GB-1 | Growth Inhibition Assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 0.56007 μM. | SANGER | ||
| A4-Fuk | Growth Inhibition Assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50 = 0.56048 μM. | SANGER | ||
| A375 | Growth Inhibition Assay | Inhibition of human A375 cell growth in a cell viability assay, IC50 = 0.56103 μM. | SANGER | ||
| CAL-85-1 | Growth Inhibition Assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50 = 0.56518 μM. | SANGER | ||
| BC-1 | Growth Inhibition Assay | Inhibition of human BC-1 cell growth in a cell viability assay, IC50 = 0.56558 μM. | SANGER | ||
| SCC-15 | Growth Inhibition Assay | Inhibition of human SCC-15 cell growth in a cell viability assay, IC50 = 0.57407 μM. | SANGER | ||
| RPMI-8402 | Growth Inhibition Assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50 = 0.57766 μM. | SANGER | ||
| OAW-42 | Growth Inhibition Assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50 = 0.58091 μM. | SANGER | ||
| A101D | Growth Inhibition Assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 0.58789 μM. | SANGER | ||
| RPMI-7951 | Growth Inhibition Assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50 = 0.61123 μM. | SANGER | ||
| TE-12 | Growth Inhibition Assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50 = 0.61199 μM. | SANGER | ||
| P30-OHK | Growth Inhibition Assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 0.61246 μM. | SANGER | ||
| KP-4 | Growth Inhibition Assay | Inhibition of human KP-4 cell growth in a cell viability assay, IC50 = 0.61585 μM. | SANGER | ||
| U251 | Growth Inhibition Assay | Inhibition of human U251 cell growth in a cell viability assay, IC50 = 0.61621 μM. | SANGER | ||
| RS4-11 | Growth Inhibition Assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 0.62417 μM. | SANGER | ||
| CA46 | Growth Inhibition Assay | Inhibition of human CA46 cell growth in a cell viability assay, IC50 = 0.62885 μM. | SANGER | ||
| DOK | Growth Inhibition Assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 0.6367 μM. | SANGER | ||
| NCI-H2126 | Growth Inhibition Assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50 = 0.64325 μM. | SANGER | ||
| CaR-1 | Growth Inhibition Assay | Inhibition of human CaR-1 cell growth in a cell viability assay, IC50 = 0.64476 μM. | SANGER | ||
| ACN | Growth Inhibition Assay | Inhibition of human ACN cell growth in a cell viability assay, IC50 = 0.64832 μM. | SANGER | ||
| SUP-T1 | Growth Inhibition Assay | Inhibition of human SUP-T1 cell growth in a cell viability assay, IC50 = 0.65424 μM. | SANGER | ||
| KALS-1 | Growth Inhibition Assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50 = 0.65903 μM. | SANGER | ||
| 697 | Growth Inhibition Assay | Inhibition of human 697 cell growth in a cell viability assay, IC50 = 0.67132 μM. | SANGER | ||
| NCI-H2087 | Growth Inhibition Assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 0.67782 μM. | SANGER | ||
| NCI-H1355 | Growth Inhibition Assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 0.67816 μM. | SANGER | ||
| EW-7 | Growth Inhibition Assay | Inhibition of human EW-7 cell growth in a cell viability assay, IC50 = 0.68195 μM. | SANGER | ||
| OVCAR-5 | Growth Inhibition Assay | Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50 = 0.69167 μM. | SANGER | ||
| HOP-92 | Growth Inhibition Assay | Inhibition of human HOP-92 cell growth in a cell viability assay, IC50 = 0.69865 μM. | SANGER | ||
| NCI-H2052 | Growth Inhibition Assay | Inhibition of human NCI-H2052 cell growth in a cell viability assay, IC50 = 0.69894 μM. | SANGER | ||
| NCI-H1703 | Growth Inhibition Assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50 = 0.70473 μM. | SANGER | ||
| NCI-H719 | Growth Inhibition Assay | Inhibition of human NCI-H719 cell growth in a cell viability assay, IC50 = 0.70676 μM. | SANGER | ||
| MC116 | Growth Inhibition Assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50 = 0.71581 μM. | SANGER | ||
| NCI-H526 | Growth Inhibition Assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 0.71925 μM. | SANGER | ||
| MEL-HO | Growth Inhibition Assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50 = 0.72664 μM. | SANGER | ||
| AM-38 | Growth Inhibition Assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50 = 0.72871 μM. | SANGER | ||
| SW1783 | Growth Inhibition Assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50 = 0.73337 μM. | SANGER | ||
| NB69 | Growth Inhibition Assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 0.73467 μM. | SANGER | ||
| VM-CUB-1 | Growth Inhibition Assay | Inhibition of human VM-CUB-1 cell growth in a cell viability assay, IC50 = 0.7367 μM. | SANGER | ||
| LCLC-97TM1 | Growth Inhibition Assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 0.75396 μM. | SANGER | ||
| NCCIT | Growth Inhibition Assay | Inhibition of human NCCIT cell growth in a cell viability assay, IC50 = 0.76775 μM. | SANGER | ||
| SNB75 | Growth Inhibition Assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50 = 0.77311 μM. | SANGER | ||
| NCI-H292 | Growth Inhibition Assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50 = 0.77393 μM. | SANGER | ||
| NCI-H1734 | Growth Inhibition Assay | Inhibition of human NCI-H1734 cell growth in a cell viability assay, IC50 = 0.77483 μM. | SANGER | ||
| KYSE-510 | Growth Inhibition Assay | Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50 = 0.78539 μM. | SANGER | ||
| RL95-2 | Growth Inhibition Assay | Inhibition of human RL95-2 cell growth in a cell viability assay, IC50 = 0.79572 μM. | SANGER | ||
| ML-2 | Growth Inhibition Assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 0.79859 μM. | SANGER | ||
| NCI-H1793 | Growth Inhibition Assay | Inhibition of human NCI-H1793 cell growth in a cell viability assay, IC50 = 0.80088 μM. | SANGER | ||
| LOUCY | Growth Inhibition Assay | Inhibition of human LOUCY cell growth in a cell viability assay, IC50 = 0.805 μM. | SANGER | ||
| KYSE-70 | Growth Inhibition Assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50 = 0.82041 μM. | SANGER | ||
| NB13 | Growth Inhibition Assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50 = 0.82057 μM. | SANGER | ||
| A3-KAW | Growth Inhibition Assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 0.83993 μM. | SANGER | ||
| GR-ST | Growth Inhibition Assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 0.87237 μM. | SANGER | ||
| SCC-9 | Growth Inhibition Assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 0.87286 μM. | SANGER | ||
| HCC1599 | Growth Inhibition Assay | Inhibition of human HCC1599 cell growth in a cell viability assay, IC50 = 0.8791 μM. | SANGER | ||
| MKN1 | Growth Inhibition Assay | Inhibition of human MKN1 cell growth in a cell viability assay, IC50 = 0.88412 μM. | SANGER | ||
| NCI-H1650 | Growth Inhibition Assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 0.88916 μM. | SANGER | ||
| LS-1034 | Growth Inhibition Assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50 = 0.90528 μM. | SANGER | ||
| 639-V | Growth Inhibition Assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 0.92063 μM. | SANGER | ||
| BL-41 | Growth Inhibition Assay | Inhibition of human BL-41 cell growth in a cell viability assay, IC50 = 0.92539 μM. | SANGER | ||
| HT-1376 | Growth Inhibition Assay | Inhibition of human HT-1376 cell growth in a cell viability assay, IC50 = 0.92918 μM. | SANGER | ||
| CAL-62 | Growth Inhibition Assay | Inhibition of human CAL-62 cell growth in a cell viability assay, IC50 = 0.93235 μM. | SANGER | ||
| DBTRG-05MG | Growth Inhibition Assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50 = 0.94197 μM. | SANGER | ||
| SW872 | Growth Inhibition Assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50 = 0.94459 μM. | SANGER | ||
| RT-112 | Growth Inhibition Assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 0.97483 μM. | SANGER | ||
| HT-29 | Growth Inhibition Assay | Inhibition of human HT-29 cell growth in a cell viability assay, IC50 = 0.97996 μM. | SANGER | ||
| U-266 | Growth Inhibition Assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 0.98302 μM. | SANGER | ||
| HEL | Growth Inhibition Assay | Inhibition of human HEL cell growth in a cell viability assay, IC50 = 0.98517 μM. | SANGER | ||
| LB2241-RCC | Growth Inhibition Assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50 = 0.98707 μM. | SANGER | ||
| TE-441-T | Growth Inhibition Assay | Inhibition of human TE-441-T cell growth in a cell viability assay, IC50 = 0.99434 μM. | SANGER | ||
| UM-UC-3 | Growth Inhibition Assay | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50 = 1.00689 μM. | SANGER | ||
| DSH1 | Growth Inhibition Assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50 = 1.02389 μM. | SANGER | ||
| SCC-25 | Growth Inhibition Assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 1.04887 μM. | SANGER | ||
| OAW-28 | Growth Inhibition Assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50 = 1.0569 μM. | SANGER | ||
| TE-11 | Growth Inhibition Assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 1.07154 μM. | SANGER | ||
| RD | Growth Inhibition Assay | Inhibition of human RD cell growth in a cell viability assay, IC50 = 1.07208 μM. | SANGER | ||
| ESS-1 | Growth Inhibition Assay | Inhibition of human ESS-1 cell growth in a cell viability assay, IC50 = 1.07618 μM. | SANGER | ||
| CMK | Growth Inhibition Assay | Inhibition of human CMK cell growth in a cell viability assay, IC50 = 1.09082 μM. | SANGER | ||
| KURAMOCHI | Growth Inhibition Assay | Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50 = 1.10935 μM. | SANGER | ||
| KU812 | Growth Inhibition Assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50 = 1.11164 μM. | SANGER | ||
| COLO-668 | Growth Inhibition Assay | Inhibition of human COLO-668 cell growth in a cell viability assay, IC50 = 1.12232 μM. | SANGER | ||
| KYSE-140 | Growth Inhibition Assay | Inhibition of human KYSE-140 cell growth in a cell viability assay, IC50 = 1.14444 μM. | SANGER | ||
| NCI-H716 | Growth Inhibition Assay | Inhibition of human NCI-H716 cell growth in a cell viability assay, IC50 = 1.15487 μM. | SANGER | ||
| ES4 | Growth Inhibition Assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50 = 1.16462 μM. | SANGER | ||
| SW626 | Growth Inhibition Assay | Inhibition of human SW626 cell growth in a cell viability assay, IC50 = 1.16813 μM. | SANGER | ||
| U-2-OS | Growth Inhibition Assay | Inhibition of human U-2-OS cell growth in a cell viability assay, IC50 = 1.16996 μM. | SANGER | ||
| HCC1569 | Growth Inhibition Assay | Inhibition of human HCC1569 cell growth in a cell viability assay, IC50 = 1.17018 μM. | SANGER | ||
| A673 | Growth Inhibition Assay | Inhibition of human A673 cell growth in a cell viability assay, IC50 = 1.17069 μM. | SANGER | ||
| GAMG | Growth Inhibition Assay | Inhibition of human GAMG cell growth in a cell viability assay, IC50 = 1.17866 μM. | SANGER | ||
| FADU | Growth Inhibition Assay | Inhibition of human FADU cell growth in a cell viability assay, IC50 = 1.18547 μM. | SANGER | ||
| MKN28 | Growth Inhibition Assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50 = 1.19816 μM. | SANGER | ||
| DB | Growth Inhibition Assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 1.21929 μM. | SANGER | ||
| ES8 | Growth Inhibition Assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50 = 1.22304 μM. | SANGER | ||
| OVCAR-3 | Growth Inhibition Assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50 = 1.22696 μM. | SANGER | ||
| SW954 | Growth Inhibition Assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50 = 1.25911 μM. | SANGER | ||
| ECC4 | Growth Inhibition Assay | Inhibition of human ECC4 cell growth in a cell viability assay, IC50 = 1.26182 μM. | SANGER | ||
| SK-MEL-3 | Growth Inhibition Assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 1.26372 μM. | SANGER | ||
| SBC-5 | Growth Inhibition Assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50 = 1.27389 μM. | SANGER | ||
| TE-10 | Growth Inhibition Assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50 = 1.2814 μM. | SANGER | ||
| NCI-H630 | Growth Inhibition Assay | Inhibition of human NCI-H630 cell growth in a cell viability assay, IC50 = 1.28805 μM. | SANGER | ||
| EGI-1 | Growth Inhibition Assay | Inhibition of human EGI-1 cell growth in a cell viability assay, IC50 = 1.30089 μM. | SANGER | ||
| NCI-H1770 | Growth Inhibition Assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50 = 1.31382 μM. | SANGER | ||
| ES5 | Growth Inhibition Assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50 = 1.32981 μM. | SANGER | ||
| Daoy | Growth Inhibition Assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50 = 1.3357 μM. | SANGER | ||
| OCUB-M | Growth Inhibition Assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50 = 1.35915 μM. | SANGER | ||
| WSU-NHL | Growth Inhibition Assay | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50 = 1.39185 μM. | SANGER | ||
| M059J | Growth Inhibition Assay | Inhibition of human M059J cell growth in a cell viability assay, IC50 = 1.39231 μM. | SANGER | ||
| NCI-H69 | Growth Inhibition Assay | Inhibition of human NCI-H69 cell growth in a cell viability assay, IC50 = 1.39549 μM. | SANGER | ||
| NH-12 | Growth Inhibition Assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 1.40262 μM. | SANGER | ||
| COLO-800 | Growth Inhibition Assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50 = 1.4036 μM. | SANGER | ||
| NB6 | Growth Inhibition Assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50 = 1.4446 μM. | SANGER | ||
| C3A | Growth Inhibition Assay | Inhibition of human C3A cell growth in a cell viability assay, IC50 = 1.44539 μM. | SANGER | ||
| BB65-RCC | Growth Inhibition Assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50 = 1.47436 μM. | SANGER | ||
| CTB-1 | Growth Inhibition Assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50 = 1.486 μM. | SANGER | ||
| HCC1806 | Growth Inhibition Assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50 = 1.53072 μM. | SANGER | ||
| TE-15 | Growth Inhibition Assay | Inhibition of human TE-15 cell growth in a cell viability assay, IC50 = 1.53748 μM. | SANGER | ||
| GMS-10 | Growth Inhibition Assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 1.53837 μM. | SANGER | ||
| ES7 | Growth Inhibition Assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50 = 1.53848 μM. | SANGER | ||
| RO82-W-1 | Growth Inhibition Assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50 = 1.54406 μM. | SANGER | ||
| NCI-H1522 | Growth Inhibition Assay | Inhibition of human NCI-H1522 cell growth in a cell viability assay, IC50 = 1.545 μM. | SANGER | ||
| IST-MES1 | Growth Inhibition Assay | Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50 = 1.56074 μM. | SANGER | ||
| EM-2 | Growth Inhibition Assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 1.56554 μM. | SANGER | ||
| NUGC-3 | Growth Inhibition Assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 1.56928 μM. | SANGER | ||
| BOKU | Growth Inhibition Assay | Inhibition of human BOKU cell growth in a cell viability assay, IC50 = 1.5697 μM. | SANGER | ||
| DK-MG | Growth Inhibition Assay | Inhibition of human DK-MG cell growth in a cell viability assay, IC50 = 1.58048 μM. | SANGER | ||
| SW620 | Growth Inhibition Assay | Inhibition of human SW620 cell growth in a cell viability assay, IC50 = 1.61701 μM. | SANGER | ||
| NCI-H1693 | Growth Inhibition Assay | Inhibition of human NCI-H1693 cell growth in a cell viability assay, IC50 = 1.63492 μM. | SANGER | ||
| NCI-H838 | Growth Inhibition Assay | Inhibition of human NCI-H838 cell growth in a cell viability assay, IC50 = 1.63895 μM. | SANGER | ||
| HTC-C3 | Growth Inhibition Assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 1.64035 μM. | SANGER | ||
| TE-6 | Growth Inhibition Assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50 = 1.64833 μM. | SANGER | ||
| QIMR-WIL | Growth Inhibition Assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50 = 1.65364 μM. | SANGER | ||
| OPM-2 | Growth Inhibition Assay | Inhibition of human OPM-2 cell growth in a cell viability assay, IC50 = 1.65801 μM. | SANGER | ||
| TE-8 | Growth Inhibition Assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50 = 1.679 μM. | SANGER | ||
| MFE-296 | Growth Inhibition Assay | Inhibition of human MFE-296 cell growth in a cell viability assay, IC50 = 1.67951 μM. | SANGER | ||
| 8305C | Growth Inhibition Assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 1.68034 μM. | SANGER | ||
| IGROV-1 | Growth Inhibition Assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50 = 1.69317 μM. | SANGER | ||
| HCC2157 | Growth Inhibition Assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50 = 1.73898 μM. | SANGER | ||
| NCI-H1436 | Growth Inhibition Assay | Inhibition of human NCI-H1436 cell growth in a cell viability assay, IC50 = 1.74054 μM. | SANGER | ||
| K052 | Growth Inhibition Assay | Inhibition of human K052 cell growth in a cell viability assay, IC50 = 1.74614 μM. | SANGER | ||
| 5637 | Growth Inhibition Assay | Inhibition of human 5637 cell growth in a cell viability assay, IC50 = 1.77422 μM. | SANGER | ||
| NCI-H747 | Growth Inhibition Assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 1.77706 μM. | SANGER | ||
| UMC-11 | Growth Inhibition Assay | Inhibition of human UMC-11 cell growth in a cell viability assay, IC50 = 1.78278 μM. | SANGER | ||
| SJRH30 | Growth Inhibition Assay | Inhibition of human SJRH30 cell growth in a cell viability assay, IC50 = 1.7888 μM. | SANGER | ||
| HMV-II | Growth Inhibition Assay | Inhibition of human HMV-II cell growth in a cell viability assay, IC50 = 1.79386 μM. | SANGER | ||
| HSC-3 | Growth Inhibition Assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50 = 1.81675 μM. | SANGER | ||
| CESS | Growth Inhibition Assay | Inhibition of human CESS cell growth in a cell viability assay, IC50 = 1.8191 μM. | SANGER | ||
| MN-60 | Growth Inhibition Assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 1.83489 μM. | SANGER | ||
| OVCAR-4 | Growth Inhibition Assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 1.8477 μM. | SANGER | ||
| RCC10RGB | Growth Inhibition Assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 1.85868 μM. | SANGER | ||
| Caov-4 | Growth Inhibition Assay | Inhibition of human Caov-4 cell growth in a cell viability assay, IC50 = 1.91696 μM. | SANGER | ||
| T-24 | Growth Inhibition Assay | Inhibition of human T-24 cell growth in a cell viability assay, IC50 = 1.91893 μM. | SANGER | ||
| HCE-T | Growth Inhibition Assay | Inhibition of human HCE-T cell growth in a cell viability assay, IC50 = 1.93451 μM. | SANGER | ||
| NCI-H1618 | Growth Inhibition Assay | Inhibition of human NCI-H1618 cell growth in a cell viability assay, IC50 = 1.95521 μM. | SANGER | ||
| GOTO | Growth Inhibition Assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50 = 1.95832 μM. | SANGER | ||
| CTV-1 | Growth Inhibition Assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 2.01635 μM. | SANGER | ||
| NCI-H661 | Growth Inhibition Assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50 = 2.02361 μM. | SANGER | ||
| OVCAR-8 | Growth Inhibition Assay | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50 = 2.0315 μM. | SANGER | ||
| OCI-AML2 | Growth Inhibition Assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 2.07476 μM. | SANGER | ||
| GP5d | Growth Inhibition Assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50 = 2.07534 μM. | SANGER | ||
| IM-9 | Growth Inhibition Assay | Inhibition of human IM-9 cell growth in a cell viability assay, IC50 = 2.10517 μM. | SANGER | ||
| Calu-1 | Growth Inhibition Assay | Inhibition of human Calu-1 cell growth in a cell viability assay, IC50 = 2.12405 μM. | SANGER | ||
| LC-1F | Growth Inhibition Assay | Inhibition of human LC-1F cell growth in a cell viability assay, IC50 = 2.14764 μM. | SANGER | ||
| NEC8 | Growth Inhibition Assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50 = 2.15601 μM. | SANGER | ||
| SK-MM-2 | Growth Inhibition Assay | Inhibition of human SK-MM-2 cell growth in a cell viability assay, IC50 = 2.17622 μM. | SANGER | ||
| BHT-101 | Growth Inhibition Assay | Inhibition of human BHT-101 cell growth in a cell viability assay, IC50 = 2.19654 μM. | SANGER | ||
| IST-MEL1 | Growth Inhibition Assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 2.2183 μM. | SANGER | ||
| NCI-H1648 | Growth Inhibition Assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50 = 2.23428 μM. | SANGER | ||
| DV-90 | Growth Inhibition Assay | Inhibition of human DV-90 cell growth in a cell viability assay, IC50 = 2.24215 μM. | SANGER | ||
| CAPAN-1 | Growth Inhibition Assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50 = 2.24787 μM. | SANGER | ||
| C-33-A | Growth Inhibition Assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50 = 2.26063 μM. | SANGER | ||
| SW1573 | Growth Inhibition Assay | Inhibition of human SW1573 cell growth in a cell viability assay, IC50 = 2.28472 μM. | SANGER | ||
| NCI-H1304 | Growth Inhibition Assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50 = 2.28867 μM. | SANGER | ||
| RCM-1 | Growth Inhibition Assay | Inhibition of human RCM-1 cell growth in a cell viability assay, IC50 = 2.29298 μM. | SANGER | ||
| KINGS-1 | Growth Inhibition Assay | Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50 = 2.30271 μM. | SANGER | ||
| Hs-578-T | Growth Inhibition Assay | Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50 = 2.30709 μM. | SANGER | ||
| KLE | Growth Inhibition Assay | Inhibition of human KLE cell growth in a cell viability assay, IC50 = 2.30734 μM. | SANGER | ||
| BHY | Growth Inhibition Assay | Inhibition of human BHY cell growth in a cell viability assay, IC50 = 2.34912 μM. | SANGER | ||
| WM-115 | Growth Inhibition Assay | Inhibition of human WM-115 cell growth in a cell viability assay, IC50 = 2.35968 μM. | SANGER | ||
| JiyoyeP-2003 | Growth Inhibition Assay | Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50 = 2.36405 μM. | SANGER | ||
| NCI-H2228 | Growth Inhibition Assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 2.38384 μM. | SANGER | ||
| NCI-H226 | Growth Inhibition Assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 2.38663 μM. | SANGER | ||
| HCC70 | Growth Inhibition Assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 2.44949 μM. | SANGER | ||
| SK-PN-DW | Growth Inhibition Assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50 = 2.46029 μM. | SANGER | ||
| KYSE-450 | Growth Inhibition Assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50 = 2.59202 μM. | SANGER | ||
| SN12C | Growth Inhibition Assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50 = 2.6275 μM. | SANGER | ||
| U-87-MG | Growth Inhibition Assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50 = 2.68124 μM. | SANGER | ||
| Becker | Growth Inhibition Assay | Inhibition of human Becker cell growth in a cell viability assay, IC50 = 2.69475 μM. | SANGER | ||
| NCI-SNU-1 | Growth Inhibition Assay | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50 = 2.70325 μM. | SANGER | ||
| IST-SL1 | Growth Inhibition Assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50 = 2.70327 μM. | SANGER | ||
| SIMA | Growth Inhibition Assay | Inhibition of human SIMA cell growth in a cell viability assay, IC50 = 2.7086 μM. | SANGER | ||
| IMR-5 | Growth Inhibition Assay | Inhibition of human IMR-5 cell growth in a cell viability assay, IC50 = 2.71465 μM. | SANGER | ||
| COLO-678 | Growth Inhibition Assay | Inhibition of human COLO-678 cell growth in a cell viability assay, IC50 = 2.73477 μM. | SANGER | ||
| LS-411N | Growth Inhibition Assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 2.74999 μM. | SANGER | ||
| Capan-2 | Growth Inhibition Assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 2.7664 μM. | SANGER | ||
| HT55 | Growth Inhibition Assay | Inhibition of human HT55 cell growth in a cell viability assay, IC50 = 2.77321 μM. | SANGER | ||
| RPMI-2650 | Growth Inhibition Assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50 = 2.78633 μM. | SANGER | ||
| HuH-7 | Growth Inhibition Assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 2.78923 μM. | SANGER | ||
| NCI-H2452 | Growth Inhibition Assay | Inhibition of human NCI-H2452 cell growth in a cell viability assay, IC50 = 2.80514 μM. | SANGER | ||
| RMG-I | Growth Inhibition Assay | Inhibition of human RMG-I cell growth in a cell viability assay, IC50 = 2.86407 μM. | SANGER | ||
| NCI-H2347 | Growth Inhibition Assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 2.86973 μM. | SANGER | ||
| COLO-824 | Growth Inhibition Assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50 = 2.88433 μM. | SANGER | ||
| HC-1 | Growth Inhibition Assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50 = 2.89529 μM. | SANGER | ||
| ChaGo-K-1 | Growth Inhibition Assay | Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50 = 2.89815 μM. | SANGER | ||
| Ramos-2G6-4C10 | Growth Inhibition Assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 2.94387 μM. | SANGER | ||
| SK-MEL-2 | Growth Inhibition Assay | Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50 = 2.97003 μM. | SANGER | ||
| NCI-H64 | Growth Inhibition Assay | Inhibition of human NCI-H64 cell growth in a cell viability assay, IC50 = 3.00372 μM. | SANGER | ||
| MHH-NB-11 | Growth Inhibition Assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 3.01878 μM. | SANGER | ||
| SU-DHL-1 | Growth Inhibition Assay | Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50 = 3.06959 μM. | SANGER | ||
| NOS-1 | Growth Inhibition Assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50 = 3.09872 μM. | SANGER | ||
| ARH-77 | Growth Inhibition Assay | Inhibition of human ARH-77 cell growth in a cell viability assay, IC50 = 3.14605 μM. | SANGER | ||
| HO-1-N-1 | Growth Inhibition Assay | Inhibition of human HO-1-N-1 cell growth in a cell viability assay, IC50 = 3.15569 μM. | SANGER | ||
| TGBC1TKB | Growth Inhibition Assay | Inhibition of human TGBC1TKB cell growth in a cell viability assay, IC50 = 3.17557 μM. | SANGER | ||
| HuP-T3 | Growth Inhibition Assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 3.2079 μM. | SANGER | ||
| BEN | Growth Inhibition Assay | Inhibition of human BEN cell growth in a cell viability assay, IC50 = 3.21481 μM. | SANGER | ||
| HGC-27 | Growth Inhibition Assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50 = 3.2299 μM. | SANGER | ||
| no-11 | Growth Inhibition Assay | Inhibition of human no-11 cell growth in a cell viability assay, IC50 = 3.23209 μM. | SANGER | ||
| NCI-H460 | Growth Inhibition Assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50 = 3.26306 μM. | SANGER | ||
| COLO-684 | Growth Inhibition Assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 3.34745 μM. | SANGER | ||
| RPMI-6666 | Growth Inhibition Assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50 = 3.41159 μM. | SANGER | ||
| NCI-H1993 | Growth Inhibition Assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50 = 3.53667 μM. | SANGER | ||
| IPC-298 | Growth Inhibition Assay | Inhibition of human IPC-298 cell growth in a cell viability assay, IC50 = 3.55672 μM. | SANGER | ||
| NCI-H1437 | Growth Inhibition Assay | Inhibition of human NCI-H1437 cell growth in a cell viability assay, IC50 = 3.55932 μM. | SANGER | ||
| COR-L279 | Growth Inhibition Assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50 = 3.56357 μM. | SANGER | ||
| BT-20 | Growth Inhibition Assay | Inhibition of human BT-20 cell growth in a cell viability assay, IC50 = 3.6653 μM. | SANGER | ||
| LK-2 | Growth Inhibition Assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50 = 3.71552 μM. | SANGER | ||
| Saos-2 | Growth Inhibition Assay | Inhibition of human Saos-2 cell growth in a cell viability assay, IC50 = 3.7428 μM. | SANGER | ||
| SKG-IIIa | Growth Inhibition Assay | Inhibition of human SKG-IIIa cell growth in a cell viability assay, IC50 = 3.76572 μM. | SANGER | ||
| MC-CAR | Growth Inhibition Assay | Inhibition of human MC-CAR cell growth in a cell viability assay, IC50 = 3.78133 μM. | SANGER | ||
| UACC-257 | Growth Inhibition Assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 3.81844 μM. | SANGER | ||
| DU-4475 | Growth Inhibition Assay | Inhibition of human DU-4475 cell growth in a cell viability assay, IC50 = 3.87134 μM. | SANGER | ||
| RERF-LC-MS | Growth Inhibition Assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50 = 3.98353 μM. | SANGER | ||
| LB996-RCC | Growth Inhibition Assay | Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50 = 3.98644 μM. | SANGER | ||
| ES3 | Growth Inhibition Assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50 = 4.05557 μM. | SANGER | ||
| MMAC-SF | Growth Inhibition Assay | Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50 = 4.05847 μM. | SANGER | ||
| MEG-01 | Growth Inhibition Assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 4.06297 μM. | SANGER | ||
| TE-1 | Growth Inhibition Assay | Inhibition of human TE-1 cell growth in a cell viability assay, IC50 = 4.09458 μM. | SANGER | ||
| ES6 | Growth Inhibition Assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50 = 4.10666 μM. | SANGER | ||
| NCI-H1963 | Growth Inhibition Assay | Inhibition of human NCI-H1963 cell growth in a cell viability assay, IC50 = 4.11351 μM. | SANGER | ||
| MZ7-mel | Growth Inhibition Assay | Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50 = 4.15662 μM. | SANGER | ||
| COLO-679 | Growth Inhibition Assay | Inhibition of human COLO-679 cell growth in a cell viability assay, IC50 = 4.16629 μM. | SANGER | ||
| LB647-SCLC | Growth Inhibition Assay | Inhibition of human LB647-SCLC cell growth in a cell viability assay, IC50 = 4.22508 μM. | SANGER | ||
| LoVo | Growth Inhibition Assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 4.22985 μM. | SANGER | ||
| UACC-62 | Growth Inhibition Assay | Inhibition of human UACC-62 cell growth in a cell viability assay, IC50 = 4.25764 μM. | SANGER | ||
| BE-13 | Growth Inhibition Assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50 = 4.36027 μM. | SANGER | ||
| SW962 | Growth Inhibition Assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 4.36427 μM. | SANGER | ||
| HEC-1 | Growth Inhibition Assay | Inhibition of human HEC-1 cell growth in a cell viability assay, IC50 = 4.39433 μM. | SANGER | ||
| KOSC-2 | Growth Inhibition Assay | Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50 = 4.39928 μM. | SANGER | ||
| HSC-4 | Growth Inhibition Assay | Inhibition of human HSC-4 cell growth in a cell viability assay, IC50 = 4.40337 μM. | SANGER | ||
| J82 | Growth Inhibition Assay | Inhibition of human J82 cell growth in a cell viability assay, IC50 = 4.43178 μM. | SANGER | ||
| MLMA | Growth Inhibition Assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50 = 4.4609 μM. | SANGER | ||
| LU-165 | Growth Inhibition Assay | Inhibition of human LU-165 cell growth in a cell viability assay, IC50 = 4.46513 μM. | SANGER | ||
| C8166 | Growth Inhibition Assay | Inhibition of human C8166 cell growth in a cell viability assay, IC50 = 4.48793 μM. | SANGER | ||
| LC4-1 | Growth Inhibition Assay | Inhibition of human LC4-1 cell growth in a cell viability assay, IC50 = 4.51096 μM. | SANGER | ||
| RT4 | Growth Inhibition Assay | Inhibition of human RT4 cell growth in a cell viability assay, IC50 = 4.61734 μM. | SANGER | ||
| 23132-87 | Growth Inhibition Assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50 = 4.63837 μM. | SANGER | ||
| COLO-320-HSR | Growth Inhibition Assay | Inhibition of human COLO-320-HSR cell growth in a cell viability assay, IC50 = 4.64656 μM. | SANGER | ||
| KARPAS-45 | Growth Inhibition Assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 4.65165 μM. | SANGER | ||
| LU-65 | Growth Inhibition Assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50 = 4.65198 μM. | SANGER | ||
| PC-3 | Growth Inhibition Assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50 = 4.66509 μM. | SANGER | ||
| IA-LM | Growth Inhibition Assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50 = 4.70635 μM. | SANGER | ||
| SW684 | Growth Inhibition Assay | Inhibition of human SW684 cell growth in a cell viability assay, IC50 = 4.78838 μM. | SANGER | ||
| MDA-MB-134-VI | Growth Inhibition Assay | Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay, IC50 = 4.79107 μM. | SANGER | ||
| KMOE-2 | Growth Inhibition Assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50 = 4.79789 μM. | SANGER | ||
| PANC-08-13 | Growth Inhibition Assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50 = 4.80463 μM. | SANGER | ||
| NB12 | Growth Inhibition Assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50 = 4.83764 μM. | SANGER | ||
| CHP-126 | Growth Inhibition Assay | Inhibition of human CHP-126 cell growth in a cell viability assay, IC50 = 4.84468 μM. | SANGER | ||
| HH | Growth Inhibition Assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 4.89303 μM. | SANGER | ||
| A253 | Growth Inhibition Assay | Inhibition of human A253 cell growth in a cell viability assay, IC50 = 4.90307 μM. | SANGER | ||
| MS-1 | Growth Inhibition Assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 4.92448 μM. | SANGER | ||
| OE33 | Growth Inhibition Assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50 = 4.98609 μM. | SANGER | ||
| LU-134-A | Growth Inhibition Assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50 = 5.00007 μM. | SANGER | ||
| NCI-H441 | Growth Inhibition Assay | Inhibition of human NCI-H441 cell growth in a cell viability assay, IC50 = 5.07203 μM. | SANGER | ||
| Daudi | Growth Inhibition Assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50 = 5.09119 μM. | SANGER | ||
| EHEB | Growth Inhibition Assay | Inhibition of human EHEB cell growth in a cell viability assay, IC50 = 5.11224 μM. | SANGER | ||
| SNU-C1 | Growth Inhibition Assay | Inhibition of human SNU-C1 cell growth in a cell viability assay, IC50 = 5.16875 μM. | SANGER | ||
| TGBC24TKB | Growth Inhibition Assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 5.20055 μM. | SANGER | ||
| T47D | Growth Inhibition Assay | Inhibition of human T47D cell growth in a cell viability assay, IC50 = 5.24803 μM. | SANGER | ||
| NCI-N87 | Growth Inhibition Assay | Inhibition of human NCI-N87 cell growth in a cell viability assay, IC50 = 5.32699 μM. | SANGER | ||
| MFE-280 | Growth Inhibition Assay | Inhibition of human MFE-280 cell growth in a cell viability assay, IC50 = 5.39569 μM. | SANGER | ||
| KNS-81-FD | Growth Inhibition Assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50 = 5.43617 μM. | SANGER | ||
| BV-173 | Growth Inhibition Assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50 = 5.44899 μM. | SANGER | ||
| L-363 | Growth Inhibition Assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 5.48279 μM. | SANGER | ||
| SW1417 | Growth Inhibition Assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 5.50405 μM. | SANGER | ||
| OE19 | Growth Inhibition Assay | Inhibition of human OE19 cell growth in a cell viability assay, IC50 = 5.51721 μM. | SANGER | ||
| AU565 | Growth Inhibition Assay | Inhibition of human AU565 cell growth in a cell viability assay, IC50 = 5.54849 μM. | SANGER | ||
| EB-3 | Growth Inhibition Assay | Inhibition of human EB-3 cell growth in a cell viability assay, IC50 = 5.59768 μM. | SANGER | ||
| LS-123 | Growth Inhibition Assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50 = 5.63714 μM. | SANGER | ||
| Detroit562 | Growth Inhibition Assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50 = 5.66765 μM. | SANGER | ||
| MZ2-MEL | Growth Inhibition Assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 5.66902 μM. | SANGER | ||
| SK-OV-3 | Growth Inhibition Assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50 = 5.7181 μM. | SANGER | ||
| BB49-HNC | Growth Inhibition Assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 5.7794 μM. | SANGER | ||
| L-428 | Growth Inhibition Assay | Inhibition of human L-428 cell growth in a cell viability assay, IC50 = 5.83896 μM. | SANGER | ||
| D-502MG | Growth Inhibition Assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50 = 5.84231 μM. | SANGER | ||
| IST-SL2 | Growth Inhibition Assay | Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50 = 6.00753 μM. | SANGER | ||
| MHH-PREB-1 | Growth Inhibition Assay | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50 = 6.09945 μM. | SANGER | ||
| LB2518-MEL | Growth Inhibition Assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50 = 6.25712 μM. | SANGER | ||
| MOLT-16 | Growth Inhibition Assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 6.37751 μM. | SANGER | ||
| EW-3 | Growth Inhibition Assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50 = 6.49826 μM. | SANGER | ||
| SW13 | Growth Inhibition Assay | Inhibition of human SW13 cell growth in a cell viability assay, IC50 = 6.54451 μM. | SANGER | ||
| MDA-MB-175-VII | Growth Inhibition Assay | Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay, IC50 = 6.59915 μM. | SANGER | ||
| NCI-H1651 | Growth Inhibition Assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 6.70771 μM. | SANGER | ||
| TE-9 | Growth Inhibition Assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50 = 6.72501 μM. | SANGER | ||
| MOLT-4 | Growth Inhibition Assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 6.73673 μM. | SANGER | ||
| SHP-77 | Growth Inhibition Assay | Inhibition of human SHP-77 cell growth in a cell viability assay, IC50 = 6.87231 μM. | SANGER | ||
| HN | Growth Inhibition Assay | Inhibition of human HN cell growth in a cell viability assay, IC50 = 6.99041 μM. | SANGER | ||
| NCI-H2196 | Growth Inhibition Assay | Inhibition of human NCI-H2196 cell growth in a cell viability assay, IC50 = 7.07134 μM. | SANGER | ||
| HT-3 | Growth Inhibition Assay | Inhibition of human HT-3 cell growth in a cell viability assay, IC50 = 7.10261 μM. | SANGER | ||
| SNU-475 | Growth Inhibition Assay | Inhibition of human SNU-475 cell growth in a cell viability assay, IC50 = 7.24992 μM. | SANGER | ||
| LAMA-84 | Growth Inhibition Assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 7.26693 μM. | SANGER | ||
| BL-70 | Growth Inhibition Assay | Inhibition of human BL-70 cell growth in a cell viability assay, IC50 = 7.58685 μM. | SANGER | ||
| HCC1187 | Growth Inhibition Assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50 = 7.90746 μM. | SANGER | ||
| CHL-1 | Growth Inhibition Assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50 = 7.9551 μM. | SANGER | ||
| LOXIMVI | Growth Inhibition Assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 7.98834 μM. | SANGER | ||
| NCI-H748 | Growth Inhibition Assay | Inhibition of human NCI-H748 cell growth in a cell viability assay, IC50 = 8.06778 μM. | SANGER | ||
| LB771-HNC | Growth Inhibition Assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50 = 8.1383 μM. | SANGER | ||
| JVM-2 | Growth Inhibition Assay | Inhibition of human JVM-2 cell growth in a cell viability assay, IC50 = 8.22065 μM. | SANGER | ||
| SJSA-1 | Growth Inhibition Assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50 = 8.40363 μM. | SANGER | ||
| SW1990 | Growth Inhibition Assay | Inhibition of human SW1990 cell growth in a cell viability assay, IC50 = 8.47225 μM. | SANGER | ||
| NB5 | Growth Inhibition Assay | Inhibition of human NB5 cell growth in a cell viability assay, IC50 = 8.64343 μM. | SANGER | ||
| ATN-1 | Growth Inhibition Assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50 = 8.65295 μM. | SANGER | ||
| HAL-01 | Growth Inhibition Assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50 = 8.74413 μM. | SANGER | ||
| LU-139 | Growth Inhibition Assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50 = 8.92615 μM. | SANGER | ||
| no-10 | Growth Inhibition Assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50 = 9.30633 μM. | SANGER | ||
| NCI-H1694 | Growth Inhibition Assay | Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50 = 9.37253 μM. | SANGER | ||
| COR-L88 | Growth Inhibition Assay | Inhibition of human COR-L88 cell growth in a cell viability assay, IC50 = 9.60055 μM. | SANGER | ||
| 22RV1 | Growth Inhibition Assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50 = 9.72382 μM. | SANGER | ||
| KM-H2 | Growth Inhibition Assay | Inhibition of human KM-H2 cell growth in a cell viability assay, IC50 = 9.7619 μM. | SANGER | ||
| NCI-H1092 | Growth Inhibition Assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 9.79253 μM. | SANGER | ||
| AsPC-1 | Growth Inhibition Assay | Inhibition of human AsPC-1 cell growth in a cell viability assay, IC50 = 9.85935 μM. | SANGER | ||
| MHH-CALL-2 | Growth Inhibition Assay | Inhibition of human MHH-CALL-2 cell growth in a cell viability assay, IC50 = 10.0169 μM. | SANGER | ||
| NCI-SNU-5 | Growth Inhibition Assay | Inhibition of human NCI-SNU-5 cell growth in a cell viability assay, IC50 = 10.3242 μM. | SANGER | ||
| BPH-1 | Growth Inhibition Assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50 = 10.3777 μM. | SANGER | ||
| P12-ICHIKAWA | Growth Inhibition Assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50 = 11.1095 μM. | SANGER | ||
| NCI-H727 | Growth Inhibition Assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50 = 11.1392 μM. | SANGER | ||
| COR-L23 | Growth Inhibition Assay | Inhibition of human COR-L23 cell growth in a cell viability assay, IC50 = 11.1878 μM. | SANGER | ||
| U-118-MG | Growth Inhibition Assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 11.2779 μM. | SANGER | ||
| GAK | Growth Inhibition Assay | Inhibition of human GAK cell growth in a cell viability assay, IC50 = 11.3348 μM. | SANGER | ||
| HCC2998 | Growth Inhibition Assay | Inhibition of human HCC2998 cell growth in a cell viability assay, IC50 = 11.4251 μM. | SANGER | ||
| COLO-829 | Growth Inhibition Assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50 = 11.6192 μM. | SANGER | ||
| CAL-33 | Growth Inhibition Assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50 = 11.9946 μM. | SANGER | ||
| EB2 | Growth Inhibition Assay | Inhibition of human EB2 cell growth in a cell viability assay, IC50 = 11.9968 μM. | SANGER | ||
| THP-1 | Growth Inhibition Assay | Inhibition of human THP-1 cell growth in a cell viability assay, IC50 = 12.0748 μM. | SANGER | ||
| ES1 | Growth Inhibition Assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50 = 12.0862 μM. | SANGER | ||
| 647-V | Growth Inhibition Assay | Inhibition of human 647-V cell growth in a cell viability assay, IC50 = 12.0972 μM. | SANGER | ||
| NCI-H520 | Growth Inhibition Assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50 = 12.2896 μM. | SANGER | ||
| JEG-3 | Growth Inhibition Assay | Inhibition of human JEG-3 cell growth in a cell viability assay, IC50 = 12.5281 μM. | SANGER | ||
| A388 | Growth Inhibition Assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 12.6997 μM. | SANGER | ||
| Mewo | Growth Inhibition Assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 12.8578 μM. | SANGER | ||
| KNS-42 | Growth Inhibition Assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50 = 12.9918 μM. | SANGER | ||
| MDA-MB-468 | Growth Inhibition Assay | Inhibition of human MDA-MB-468 cell growth in a cell viability assay, IC50 = 13.0366 μM. | SANGER | ||
| SiHa | Growth Inhibition Assay | Inhibition of human SiHa cell growth in a cell viability assay, IC50 = 13.1045 μM. | SANGER | ||
| C2BBe1 | Growth Inhibition Assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50 = 13.715 μM. | SANGER | ||
| HDLM-2 | Growth Inhibition Assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50 = 13.7375 μM. | SANGER | ||
| PFSK-1 | Growth Inhibition Assay | Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50 = 14.1067 μM. | SANGER | ||
| NCI-H446 | Growth Inhibition Assay | Inhibition of human NCI-H446 cell growth in a cell viability assay, IC50 = 14.3535 μM. | SANGER | ||
| EKVX | Growth Inhibition Assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50 = 14.5135 μM. | SANGER | ||
| DJM-1 | Growth Inhibition Assay | Inhibition of human DJM-1 cell growth in a cell viability assay, IC50 = 14.5549 μM. | SANGER | ||
| K-562 | Growth Inhibition Assay | Inhibition of human K-562 cell growth in a cell viability assay, IC50 = 14.5747 μM. | SANGER | ||
| CP50-MEL-B | Growth Inhibition Assay | Inhibition of human CP50-MEL-B cell growth in a cell viability assay, IC50 = 14.6287 μM. | SANGER | ||
| SK-NEP-1 | Growth Inhibition Assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 15.2382 μM. | SANGER | ||
| Ca9-22 | Growth Inhibition Assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 15.3006 μM. | SANGER | ||
| M14 | Growth Inhibition Assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 15.8452 μM. | SANGER | ||
| Calu-6 | Growth Inhibition Assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50 = 15.9582 μM. | SANGER | ||
| NCI-H1838 | Growth Inhibition Assay | Inhibition of human NCI-H1838 cell growth in a cell viability assay, IC50 = 15.9636 μM. | SANGER | ||
| T84 | Growth Inhibition Assay | Inhibition of human T84 cell growth in a cell viability assay, IC50 = 16.4497 μM. | SANGER | ||
| ME-180 | Growth Inhibition Assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50 = 17.4632 μM. | SANGER | ||
| LP-1 | Growth Inhibition Assay | Inhibition of human LP-1 cell growth in a cell viability assay, IC50 = 17.5062 μM. | SANGER | ||
| DMS-153 | Growth Inhibition Assay | Inhibition of human DMS-153 cell growth in a cell viability assay, IC50 = 18.0166 μM. | SANGER | ||
| SW1463 | Growth Inhibition Assay | Inhibition of human SW1463 cell growth in a cell viability assay, IC50 = 18.1741 μM. | SANGER | ||
| J-RT3-T3-5 | Growth Inhibition Assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 18.2392 μM. | SANGER | ||
| Ca-Ski | Growth Inhibition Assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50 = 18.5343 μM. | SANGER | ||
| CAL-148 | Growth Inhibition Assay | Inhibition of human CAL-148 cell growth in a cell viability assay, IC50 = 18.543 μM. | SANGER | ||
| NB10 | Growth Inhibition Assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50 = 18.6146 μM. | SANGER | ||
| HPAF-II | Growth Inhibition Assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 19.4871 μM. | SANGER | ||
| CAL-72 | Growth Inhibition Assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50 = 20.1775 μM. | SANGER | ||
| TT | Growth Inhibition Assay | Inhibition of human TT cell growth in a cell viability assay, IC50 = 20.2415 μM. | SANGER | ||
| RPMI-8226 | Growth Inhibition Assay | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50 = 20.3787 μM. | SANGER | ||
| D-283MED | Growth Inhibition Assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50 = 20.7314 μM. | SANGER | ||
| MIA-PaCa-2 | Growth Inhibition Assay | Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50 = 20.74 μM. | SANGER | ||
| CAMA-1 | Growth Inhibition Assay | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50 = 21.2958 μM. | SANGER | ||
| EW-24 | Growth Inhibition Assay | Inhibition of human EW-24 cell growth in a cell viability assay, IC50 = 21.296 μM. | SANGER | ||
| NCI-H2227 | Growth Inhibition Assay | Inhibition of human NCI-H2227 cell growth in a cell viability assay, IC50 = 21.3845 μM. | SANGER | ||
| SW948 | Growth Inhibition Assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 21.4582 μM. | SANGER | ||
| C32 | Growth Inhibition Assay | Inhibition of human C32 cell growth in a cell viability assay, IC50 = 21.8635 μM. | SANGER | ||
| HL-60 | Growth Inhibition Assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 22.5901 μM. | SANGER | ||
| SK-MEL-1 | Growth Inhibition Assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50 = 22.6933 μM. | SANGER | ||
| D-542MG | Growth Inhibition Assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50 = 23.1396 μM. | SANGER | ||
| NCI-H2081 | Growth Inhibition Assay | Inhibition of human NCI-H2081 cell growth in a cell viability assay, IC50 = 23.4308 μM. | SANGER | ||
| NOMO-1 | Growth Inhibition Assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 23.5328 μM. | SANGER | ||
| S-117 | Growth Inhibition Assay | Inhibition of human S-117 cell growth in a cell viability assay, IC50 = 24.1114 μM. | SANGER | ||
| KP-N-YS | Growth Inhibition Assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50 = 24.6488 μM. | SANGER | ||
| HCC1937 | Growth Inhibition Assay | Inhibition of human HCC1937 cell growth in a cell viability assay, IC50 = 24.6509 μM. | SANGER | ||
| RVH-421 | Growth Inhibition Assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50 = 24.8948 μM. | SANGER | ||
| FTC-133 | Growth Inhibition Assay | Inhibition of human FTC-133 cell growth in a cell viability assay, IC50 = 25.6658 μM. | SANGER | ||
| NCI-H1395 | Growth Inhibition Assay | Inhibition of human NCI-H1395 cell growth in a cell viability assay, IC50 = 25.9419 μM. | SANGER | ||
| KU-19-19 | Growth Inhibition Assay | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50 = 26.103 μM. | SANGER | ||
| NCI-H1623 | Growth Inhibition Assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50 = 26.1282 μM. | SANGER | ||
| LB373-MEL-D | Growth Inhibition Assay | Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50 = 26.4395 μM. | SANGER | ||
| NCI-H1882 | Growth Inhibition Assay | Inhibition of human NCI-H1882 cell growth in a cell viability assay, IC50 = 26.4574 μM. | SANGER | ||
| HT | Growth Inhibition Assay | Inhibition of human HT cell growth in a cell viability assay, IC50 = 27.1395 μM. | SANGER | ||
| SF539 | Growth Inhibition Assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 27.9248 μM. | SANGER | ||
| NCI-H2171 | Growth Inhibition Assay | Inhibition of human NCI-H2171 cell growth in a cell viability assay, IC50 = 28.6587 μM. | SANGER | ||
| MDA-MB-415 | Growth Inhibition Assay | Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50 = 29.1701 μM. | SANGER | ||
| SW756 | Growth Inhibition Assay | Inhibition of human SW756 cell growth in a cell viability assay, IC50 = 29.2866 μM. | SANGER | ||
| MDA-MB-361 | Growth Inhibition Assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 29.5408 μM. | SANGER | ||
| NCI-H1581 | Growth Inhibition Assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50 = 29.8489 μM. | SANGER | ||
| OMC-1 | Growth Inhibition Assay | Inhibition of human OMC-1 cell growth in a cell viability assay, IC50 = 30.0647 μM. | SANGER | ||
| HT-1197 | Growth Inhibition Assay | Inhibition of human HT-1197 cell growth in a cell viability assay, IC50 = 30.4937 μM. | SANGER | ||
| TE-5 | Growth Inhibition Assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50 = 31.3348 μM. | SANGER | ||
| HCC1419 | Growth Inhibition Assay | Inhibition of human HCC1419 cell growth in a cell viability assay, IC50 = 31.5056 μM. | SANGER | ||
| KE-37 | Growth Inhibition Assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50 = 31.9635 μM. | SANGER | ||
| DMS-53 | Growth Inhibition Assay | Inhibition of human DMS-53 cell growth in a cell viability assay, IC50 = 32.1035 μM. | SANGER | ||
| EW-11 | Growth Inhibition Assay | Inhibition of human EW-11 cell growth in a cell viability assay, IC50 = 32.9248 μM. | SANGER | ||
| MDA-MB-453 | Growth Inhibition Assay | Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50 = 34.2262 μM. | SANGER | ||
| SK-MEL-28 | Growth Inhibition Assay | Inhibition of human SK-MEL-28 cell growth in a cell viability assay, IC50 = 34.81 μM. | SANGER | ||
| HuP-T4 | Growth Inhibition Assay | Inhibition of human HuP-T4 cell growth in a cell viability assay, IC50 = 34.9442 μM. | SANGER | ||
| LNCaP-Clone-FGC | Growth Inhibition Assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50 = 35.3355 μM. | SANGER | ||
| SK-N-AS | Growth Inhibition Assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50 = 35.3997 μM. | SANGER | ||
| NCI-H1417 | Growth Inhibition Assay | Inhibition of human NCI-H1417 cell growth in a cell viability assay, IC50 = 35.644 μM. | SANGER | ||
| SK-N-DZ | Growth Inhibition Assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50 = 36.2005 μM. | SANGER | ||
| MKN7 | Growth Inhibition Assay | Inhibition of human MKN7 cell growth in a cell viability assay, IC50 = 36.2826 μM. | SANGER | ||
| YAPC | Growth Inhibition Assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 37.0099 μM. | SANGER | ||
| HCC1954 | Growth Inhibition Assay | Inhibition of human HCC1954 cell growth in a cell viability assay, IC50 = 37.4063 μM. | SANGER | ||
| NCI-H209 | Growth Inhibition Assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50 = 37.8896 μM. | SANGER | ||
| NCI-H2141 | Growth Inhibition Assay | Inhibition of human NCI-H2141 cell growth in a cell viability assay, IC50 = 38.0329 μM. | SANGER | ||
| LS-513 | Growth Inhibition Assay | Inhibition of human LS-513 cell growth in a cell viability assay, IC50 = 38.3118 μM. | SANGER | ||
| DOHH-2 | Growth Inhibition Assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50 = 38.9351 μM. | SANGER | ||
| NCI-H596 | Growth Inhibition Assay | Inhibition of human NCI-H596 cell growth in a cell viability assay, IC50 = 39.1801 μM. | SANGER | ||
| TYK-nu | Growth Inhibition Assay | Inhibition of human TYK-nu cell growth in a cell viability assay, IC50 = 40.3953 μM. | SANGER | ||
| CP66-MEL | Growth Inhibition Assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50 = 40.603 μM. | SANGER | ||
| SK-MEL-24 | Growth Inhibition Assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50 = 41.4873 μM. | SANGER | ||
| Caov-3 | Growth Inhibition Assay | Inhibition of human Caov-3 cell growth in a cell viability assay, IC50 = 41.5317 μM. | SANGER | ||
| HCC1143 | Growth Inhibition Assay | Inhibition of human HCC1143 cell growth in a cell viability assay, IC50 = 41.6764 μM. | SANGER | ||
| EVSA-T | Growth Inhibition Assay | Inhibition of human EVSA-T cell growth in a cell viability assay, IC50 = 42.8954 μM. | SANGER | ||
| PLC-PRF-5 | Growth Inhibition Assay | Inhibition of human PLC-PRF-5 cell growth in a cell viability assay, IC50 = 44.411 μM. | SANGER | ||
| NCI-H187 | Growth Inhibition Assay | Inhibition of human NCI-H187 cell growth in a cell viability assay, IC50 = 44.9084 μM. | SANGER | ||
| EC-GI-10 | Growth Inhibition Assay | Inhibition of human EC-GI-10 cell growth in a cell viability assay, IC50 = 46.7464 μM. | SANGER | ||
| UACC-893 | Growth Inhibition Assay | Inhibition of human UACC-893 cell growth in a cell viability assay, IC50 = 47.3736 μM. | SANGER | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Midostaurin 是一种多靶点激酶抑制剂，作用于PKCα/β/γ， Syk， Flk-1， Akt， PKA， c-Kit， c-Fgr， c-Src， FLT3， PDFRβ和VEGFR1/2，IC50为80-500 nM。 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | Midostaurin(pkc412)是一种广谱的蛋白激酶抑制剂。Midostaurin(pkc412)强烈与常规PKC-α, -β 和 -γ, PDGFRβ, VEGF-R2, VEGF-R1，及CDK 1-cyclin B复合物的ATP结合位点相互作用。Midostaurin(pkc412)在相似的亚微摩尔浓度时，在体外抑制多种人类和动物细胞系的生长。Midostaurin(pkc412) 在体外也有效抑制胶质母细胞瘤增殖，且诱导细胞在G2/M期累积，并形成巨核，具有广泛的碎片和凋亡小体。Midostaurin(pkc412)在体外能够逆转肿瘤细胞中p-糖蛋白介导的多药耐药性。[1] | |||
|---|---|---|---|---|
| 细胞实验 | 细胞系 | A549, NCI-H520 | ||
| 浓度 | ~1.0 μM | |||
| 孵育时间 | 24-72 小时 | |||
| 方法 | 每孔加入5 mM WST-1和0.2 mM 1-甲氧基PMS，然后使用酶标仪在450nm处测量吸光度。 | |||
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | p-TYR / p-STAT5 / STAT5 / p-S6 / S6 / p-MAPK / MAPK / p-AKT / AKT PKCα / PKCβ1 / PKCβ2 / PKCγ / PKCη / p-PKC / p-Bad / Bad / p-Bcl2 / Bcl-2 / p-p65 / p65 |
|
28881711 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 | Midostaurin(pkc412) 除了直接抑制肿瘤细胞增殖（通过作用于PKCs），还通过抑制肿瘤血管生成（通过作用于VEGF受体酪氨酸激酶）来抑制肿瘤的生长。Midostaurin(pkc412)与细胞毒性剂，包括Doxorubicin, Cyclophosphamide, Cisplatin 和 Gemcitabine协同作用，产生的抗血管生成作用可能有助于抗转移和广泛的抗肿瘤活性。Midostaurin(pkc412)口服给药，最大耐受剂量为300 mg/kg以上。[1] | |
|---|---|---|
| 动物实验 | Animal Models | Colo 205 结肠移植瘤 |
| Dosages | 50 mg/kg, 200 mg/kg, 每天一次 | |
| Administration | 口服处理 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05488613 | Completed | Acute Myeloid Leukemia (AML) |
Novartis Pharmaceuticals|Novartis |
September 24 2020 | -- |
| NCT03951961 | Terminated | Acute Myeloid Leukemia Adult |
University of Jena|Ludwig-Maximilians - University of Munich |
March 20 2020 | Phase 2 |
| NCT04097470 | Active not recruiting | AML/MDS |
Stichting Hemato-Oncologie voor Volwassenen Nederland|Swiss Group for Clinical Cancer Research |
December 5 2019 | Phase 2 |
化学信息&溶解度
| 分子量 | 570.64 | 分子式 | C35H30N4O4 |
| CAS号 | 120685-11-2 | SDF | Download Midostaurin SDF |
| Smiles | CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 100 mg/mL ( (175.24 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Ethanol : 2 mg/mL (3.5 mM) Water : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Midostaurin | Midostaurin supplier | purchase Midostaurin | Midostaurin cost | Midostaurin manufacturer | order Midostaurin | Midostaurin distributor
